Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesRadiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study
Journal of Neuro-Oncology, 08/27/09
Balducci M et al. – At a median follow–up of 66 months (range 3–96), median progression–free survival (PFS) was 8 months, with a 1– and 2–year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1– and 2–year OS of 69.2 and 42.3%, respectively. In the authors' experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.
Related Articles
Treatment of recurrent high-grade gliomas
Current Opinion in Neurology, 11/12/09
Relevance Score: 82%
Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT
Journal of Neuro-Oncology, 10/30/09
Relevance Score: 82%
A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma
Anticancer Research, 11/13/09
Relevance Score: 81%
Diagnostic Value of Proton Magnetic Resonance Spectroscopy in the Noninvasive Grading of Solid Gliomas: Comparison of Maximum and Mean Choline Values
Neurosurgery, 10/26/09
Relevance Score: 81%
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
Neuro-Oncology, 10/05/09
Relevance Score: 81%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies
Expert Review of Neurotherapeutics, 12/11/09
Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis
Journal of Neurosurgery: Pediatrics, 12/11/09
Central nervous system involvement at the time of presentation in acute promyelocytic leukemia
Pediatric Blood & Cancer, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor